Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money, recently emphasized ...

Eli Lilly (LLY) announced disappointing preliminary sales numbers, lowering its investor guidance for Q4. Meanwhile, Pfizer announced that a study evaluating a bladder cancer drug met a critical ...

Earnings Report 5.284 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.894 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.682 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.